Superworth

Veru free cash flow VERU

Cash from operations less capital spending, by quarter and over the last twelve months, from 2010.

Last 12 months, to Jun 30, 2026
−$26M
Latest quarter, Q3 FY26
−$5.5M
Fiscal year 2025
−$30M

Veru's free cash flow was −$26M over the twelve months to Jun 30, 2026.

In its latest quarter, Q3 FY26, it was −$5.5M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2025−$30Mn/a
FY2024−$21.8Mn/a
FY2023−$88.7Mn/a
FY2022−$48.2Mn/a
FY2021−$15.9Mn/a
FY2020−$2Mn/a
FY2019n/an/a
FY2018−$11.6M−1465%
FY2017$849.4Kn/a
FY2016−$1.7Mn/a
FY2015−$1.7M−147%
FY2014$3.6M−69%
FY2013$11.5M+19%
FY2012$9.6M+39%
FY2011$6.9Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q3 FY26−$5.5Mn/a−$26M
Q2 FY26−$8.9Mn/a−$26.1M
Q1 FY26−$6.2Mn/a−$24.9M
Q4 FY25−$5.5Mn/a−$30M
Q3 FY25−$5.5Mn/a−$29M
Q2 FY25−$7.7Mn/a−$29.2M
Q1 FY25−$11.3Mn/a−$27.2M
Q4 FY24−$4.4Mn/a−$21.8M
Q3 FY24−$5.7Mn/a−$27.1M
Q2 FY24−$5.7Mn/a−$39.9M
Q1 FY24−$6Mn/a−$59.9M
Q4 FY23−$9.7Mn/a−$88.7M

Against its peers

Companies in Drug Manufacturers - General nearest Veru's size, closest first, today.

CompanyFree cash flow yield
VERUVeru−68.2%
ATNMActinium Pharmaceuticalsn/m
SPROSpero Therapeuticsn/m
LFVNLifevantage9.1%
NATRNatures Sunshine Products8.5%
Peer median8.8%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Veru

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.